Viewing data from:

CANGRELOR

ANDA

CANGRELOR | A213551 | GLAND PHARMA LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: KENGREAL(TE code: AP)

Hatch-Waxman Litigation

2 cases on OB patents from PACER

Case	Court	Filed	Status	Judge
CHIESI USA, INC. et al v. GLAND PHARMA LTD. 2:2019cv21204 7 patentsANDA 213551cangrelor	D.N.J.	2019-12-09	Terminated 2022-06-29	—
CHIESI USA, INC. et al v. GLAND PHARMA LTD. 2:2019cv18565 8 patentsANDA 213551cangrelor	D.N.J.	2019-09-30	Terminated 2022-06-29	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain3 active DMFs

3 active API suppliers hold Drug Master Files for this ingredient.

VERANOVA LPCANGRELOR

DMF 184352005

OLON SPACANGRELOR TETRASODIUM

DMF 332952018

MSN LIFE SCIENCES PRIVATE LTDCANGRELOR TETRA SODIUM

DMF 333172018

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 12, 2022	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 50MG/VIAL

0 patents0 exclusivities▴

POWDER;INTRAVENOUS | Approved: Aug 11, 2025

No patent or exclusivity listings for this strength.